159 related articles for article (PubMed ID: 21306626)
21. Predictors of switching antipsychotic medications in the treatment of schizophrenia.
Nyhuis AW; Faries DE; Ascher-Svanum H; Stauffer VL; Kinon BJ
BMC Psychiatry; 2010 Sep; 10():75. PubMed ID: 20920179
[TBL] [Abstract][Full Text] [Related]
22. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
23. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Glick ID; Lemmens P; Vester-Blokland E
Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
[TBL] [Abstract][Full Text] [Related]
24. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
25. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Liu-Seifert H; Osuntokun OO; Feldman PD
Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
[TBL] [Abstract][Full Text] [Related]
27. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Tollefson GD; Andersen SW
J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
[TBL] [Abstract][Full Text] [Related]
28. Should the PANSS be rescaled?
Obermeier M; Mayr A; Schennach-Wolff R; Seemüller F; Möller HJ; Riedel M
Schizophr Bull; 2010 May; 36(3):455-60. PubMed ID: 19889950
[TBL] [Abstract][Full Text] [Related]
29. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
30. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
[TBL] [Abstract][Full Text] [Related]
31. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
32. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
34. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
35. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
[TBL] [Abstract][Full Text] [Related]
38. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
39. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
Kane JM; Assunção-Talbott S; Eudicone JM; Pikalov A; Whitehead R; Crandall DT
Schizophr Res; 2008 Oct; 105(1-3):208-15. PubMed ID: 18790605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
